Are Follicular Non-Hodgkin’s Lymphoma Patients Finally Getting Newer, Better Options to Treat Their Cancer?

It’s been nearly 23 years since I participated in a clinical trial after my follicular non-Hodgkin’s lymphoma recurred. When I was initially diagnosed with stage IV Follicular (FL) in early 1997, I went through five rounds of CHOP chemotherapy - cyclophosphamide, doxorubicin, vincristine and prednisone. It gave me two and 1/2 years of remission. But the treatment was rough.

When the cancer returned, instead of doing chemo again I chose to enroll in a clinical trial of a radio-immunotherapy (RIT) called Bexxar. I did my homework on the trial, and I then respectfully told my oncologist that this was my decision. He tried to talk me out of it. But I was resolute. 

 

Ultimately, my choice proved to be the right one. Multiple oncologists tell me that I am now cured of my follicular non-Hodgkin’s lymphoma. Despite the fact that many of my fellow patients were cured by Bexxar, the drug is no longer on the market for reasons that have absolutely nothing to do with its efficacy or safety.

 

Ever since Glaxo Smith Kline shelved Bexxar, as I wrote about here , and here, I've been on a mission to help my fellow follicular (FL) patients find newer, better options to treat their cancer.

 

I've worked with several dedicated, forward-thinking pharmaceutical companies to promote and encourage the study of new treatments for follicular NHL. It is desperately needed. 

But the research has been slow sledding. Follicular lymphoma, the second most common form of non-Hodgkin's lymphoma, remains an often relentless type of cancer that for many patients brings multiple relapses.

 

Since Rituxan was approved by the Food and Drug Administration (FDA) to treat follicular lymphoma in 1997, we've not seen too much movement in terms of challenging the standard of care for this horrible disease, or finding truly effective alternatives after patients recur. 

But at this month's American Society of Hematology (ASH) Annual Meeting, the largest gathering of blood cancer oncologists and scientists in the world, a boatload of promising trial data was presented from a variety of newer-generation medicines for follicular.

Viable new options are emerging at rapid pace. My hope and expectation is that some of these newer options will eventually replace the current standard of care and become first-line therapies. 

Below are just a few of the many treatments being studied that have great potential:

 

A Cell-Signal Blocker Emerges

One of the most interesting and potentially effective new drug technologies for follicular lymphoma is zandelisib. Previously called ME-401, zandelisib, from MEI Pharma in San Diego, is neither a chemotherapy nor a CAR T-cell immunotherapy nor a bispecific antibody.

Zandelisib is a cell-signal blocker. That simply means that it targets a protein in the body called P13K, which plays a key role in the growth and survival of the type of white blood cells that become abnormal in B-cell lymphomas. 

 

Blocking PI3K can help stop lymphoma cells from dividing or cause the cells to die.

MEI Pharma and Kyowa Kirin recently announced data from the Phase 2 TIDAL clinical trial of zandelisib in patients with relapsed or refractory follicular lymphoma.

In the trial, zandelisib showed a 70.3 percent objective response rate and 35.2 percent of patients achieved a complete response. And fewer than ten percent of the trial participants discontinued therapy due to side effects.

 

In an exclusive interview with The Reno Dispatch, Dan Gold, CEO at MEI Pharma and a gifted scientist who's been working in the lymphoma sector for many years, explained the status of this promising treatment. 

 

“We are very excited by the emerging zandelisib data, which indicate the potential to positively impact the standard-of-care for patients with relapsed or refractory follicular lymphoma," he said. 

 

"Once we have collected the final data from the follicular lymphoma patient cohort, we intend to discuss our plans to submit an accelerated approval marketing application with the FDA.” 

 

Gold added, "Our development efforts with our partner, Kyowa Kirin, to expand the utility of zandelisib include the ongoing Phase 3 COASTAL study evaluating zandelisib plus rituximab [Rituxan] in patients with relapsed or refractory follicular or marginal zone lymphomas.”

Bispecific Antibodies

 

But zandelisib is far from alone. There are multiple new treatments and modalities for FL that are showing very positive numbers in trials, including Roche’s Mosun.

 

In a clinical trial presented at ASH, Mosun, a bispecific antibody that redirects T cells to eliminate malignant B cells, induced "deep and durable remissions" in follicular NHL patients, including those with double-refractory disease.

 

"Notable updates coming out of ASH 2021 include experimental bispecifics such as mosunetuzumab [Mosun], which induced high response rates and durable responses for patients with relapsed/refractory follicular lymphoma,” Lee Greenberger, chief science officer at the Leukemia Society, told The Reno Dispatch.

“With a response rate of 70%, a complete response rate of 54%, and a median duration of response of 23 months, this could be a valuable addition to the treatment landscape in follicular lymphoma,"he said.

Greenberger added that Genentech's glofitamab, another bispecific for the treatment of relapsed or refractory follicular lymphoma, also showed significant response rates with good durability. 

"Bispecific antibodies offer the advantage of an off-the-shelf therapy with a performance that appears to be competitive compared to currently approved CAR T therapy for relapsed or refractory follicular lymphoma," he said. 

CAR T-Cell Immunotherapies

Not to be outdone, CAR T-cell immunotherapies, which have been the talk of the cancer research world for the last several years, are also making a strong statement about their place in the follicular space. 

 

Last March, the FDA granted Yescarta, a CAR T from Kite, a Gilead company, "accelerated approval" as a third-line therapy for adults with relapsed or refractory follicular. Yescarta, continued to shine at ASH this month, as did Kymriah, a Novartis CAR T product.

 

Both will likely challenge other drugs for third-line treatment, and eventually could become the new standard of care for FL and other types of lymphoma. 

The other good news about CAR T is that scientists continue to make progress in reducing cytokine release syndrome, the serious and sometimes even fatal side effect of this groundbreaking treatment.

 

Perhaps the most exciting piece of data in the Kymriah report presented at ASH is that no high-grade cytokine release syndrome was reported within eight weeks post-infusion and no new safety signals were identified.

"The ability to administer Kymriah, a potentially definitive treatment, in the outpatient setting may reduce the burden of therapy for patients and their care teams," Jeff Legos, global head of oncology & hematology development at Novartis, said in a press statement. 

"The breadth of follicular lymphoma data presented at this year's ASH demonstrate the potential for Kymriah to provide transformative results and a positive impact on health systems overall."

New Study: COVID-19 Breakthrough Cases Can Be A Serious Threat to Blood Cancer Patients, Including Me

As a journalist and three-time survivor of stage IV non-Hodgkin's lymphoma who is "immunocompromised," according to my oncologist, I've been reporting on the heightened threat that Covid-19 poses for lymphoma patients with great interest, and admittedly some anxiety.

As they say, denial ain't just a river in Egypt. I can neither run nor hide from the fact that there are now multiple studies worldwide showing that people with lymphoma and other blood cancers are at a substantially higher risk than healthy individuals for severe and life-threatening COVID-19 illness, and research suggests that lymphoma patients don't always achieve optimal protection from vaccination. 

A new American Society of Hematology Blood study, the first to report on post-vaccination COVID-19 cases in patients with blood cancer, offers preliminary findings about the incidence of so-called "breakthrough infection" among my fellow blood cancer patients. 

Breakthrough infection refers to people who are fully vaccinated but still get Covid-19.

The study drew data from an open online registry, EPICOVIDEHA, which collects reports of patients with blood cancers who developed COVID-19 infection. 

As of August 31, out of the 4,000 total cases in the registry, there were 113 reported cases of COVID-19 occurring after vaccination. 

More than three out of four of these breakthrough cases occurred in patients who were fully vaccinated with either the AstraZeneca vaccine or the mRNA vaccines such as Moderna or Pfizer. 

Approximately 23% had been partially vaccinated, receiving just one dose of an mRNA vaccine, when they became infected with COVID-19. 

Within the group of breakthrough cases, 79 patients experienced severe or critical COVID-19 infection, with 75 needing to be hospitalized. 

After a follow-up of 30 days post-COVID-19 diagnosis, 14 (12.4%) patients died, and COVID-19 was deemed the cause of death for all but one of those individuals. 

The study researchers emphasize that although the mortality rate in patients with breakthrough COVID-19 cases was high, it was still much lower than before vaccines were available. 

In an interview with The Reno Dispatch, study author Livio Pagano (right), MD, of the Università Cattolica del Sacro Cuore in Italy, told me, “Vaccines have significantly lowered the overall mortality rate in our patients with hematologic malignancies. Still, some patients are not showing a full protective response from vaccination, so it is important that we understand which patients are more susceptible to breakthrough infection so we can investigate how to protect them.”

This gives me some comfort, if not a lot. 

As for why lymphomas are harder hit by COVID-19 breakthrough cases, Pagano explained, “The majority of patients who do not respond to vaccination are those with lympho-proliferative disease such as lymphomas and multiple myeloma."

Pagano said these patients are often immunocompromised due to altered functionality of lymphocytes -- both from the underlying malignancy and the chemo-immune treatments -- so they do not always receive optimal protection from the vaccines.

"These patients appear to be more vulnerable to breakthrough COVID-19 infection," he said. "Patients with lymphomas are advised, even after getting the vaccine, to continue supportive measures such as wearing masks, washing hands, and reducing physical contact with other people.”

Previous studies using the registry’s data reported that during the pre-vaccination period of the pandemic, people with blood cancers and COVID-19 had mortality rates ranging from 30% to 50% (depending on type of underlying blood cancer).

“Before vaccination, if our patients with hematologic malignancies [blood cancers] developed COVID-19, they died in a lot of cases,” Pagano said in a press statement. 

“With these preliminary data, we showed that vaccination is not able to completely protect, but surely it has a strong role in reducing the mortality for COVID-19 for people with blood cancers.”

The study also found that the level of COVID-19 vaccine response was associated with the type of underlying blood cancer. 

People with myeloproliferative disorders (disorders of red blood cells and platelets) were the least likely to develop COVID-19 after vaccination, and people with lymphoproliferative disorders (disorders of lymphocytes, the white blood cells of the immune system) were the most likely. 

Of the 113 breakthrough COVID-19 cases, 80% occurred in people with lymphoproliferative conditions such as chronic lymphocytic leukemia, non-Hodgkin's lymphoma, Hodgkin's lymphoma, and multiple myeloma.

“Unfortunately, people with lymphomas are more likely to have suppressed immune systems and to develop infections, and it is no different for COVID-19,” said Dr. Pagano. 

“In future studies we will look at the efficacy of additional vaccine doses to understand if they can reduce infection in our patients, especially those with lymphoproliferative disorders.”

The type of COVID-19 vaccine did not affect the risk of breakthrough cases. 

Approximately 70% of the patients in this study received an mRNA vaccine such as the Moderna or Pfizer vaccine, and the remaining patients received the AstraZeneca vector-based vaccine or the Sinovac inactivated vaccine. 

There was no significant difference in the prevention of COVID-19 between these two groups.

“The key message is that we must make a great effort to vaccinate as many people as we can,” said Pagano. 

“We can’t only vaccinate our patients with hematologic malignancies; it is also important to vaccinate their caregivers so we can form a barrier of protection around them, because their own immunity from the vaccine is not enough.”

These are important facts that we all deserve and need to know. But they are sometimes hard for me to read and even harder to acknowledge. 

Good Friday! Joe Biden's Best Day In Office

Despite the fact that it's early November, yesterday must have felt like Good Friday for President Joe Biden. Our allegedly sleepy President was wide awake and enjoying easily his best day in office. 

Among the gifts in Biden’s seven-month late Easter basket: An excellent jobs report that left Republicans mumbling, and the overdue passage of a historic $1 trillion piece of legislation that will provide hundreds of billions to fix our roads, bridges, pipes, green energy and more, and create many jobs. His predecessor of course never got that done.

In addition, Biden’s sweeping $1.75 trillion social-spending and climate bill passed a procedural hurdle in the House and it looks like this, too, shall pass if the lefties in the democratic party stick to their word. 

Biden also announced on Friday that the U.S. economy created more than 500,000 jobs in October, far more than expected, and that unemployment dropped to 4.6 percent, it's lowest mark since May 2020 during the early days of the pandemic. 

Meanwhile, Pfizer announced on Friday that in clinical trials, its antiviral pill showed nearly 90% effectiveness rate in reducing hospitalizations and deaths from Covid. This should have a profoundly positive impact on the pandemic and global health.

Meanwhile, Biden this past week also brought the U.S. back to the global table on climate change and acknowledged that it is of course real. 

There are still problems in this economy. The supply chain issue remains a major headache, as do high gas prices, college tuition costs and jobs for minorities and women. But this past week saw far more good news than bad for the economy and for our country.

And Biden's just beginning. As Yahoo News reported yesterday, Biden and members of Congress are working out the specifics of a multi-billion dollar agreement with Black farmers as part of the Build Back Better (BBB) infrastructure spending plan.

The farmers, nearly 50,00o strong, were a big reason why Biden did so well last year in southern states that are typically red. 

What was perhaps lost in Biden's good day is the fact that the bull-market recovery from the pandemic continues. The Dow Jones soared to above 36,000 points for the first time ever. 

When you look a little closer at the increase, a percentage rise of just 2.9 percent, it may not look quite as impressive. But given where this economy and this country was, it is even more reason for optimism. 

Lest we all forget, and I think many of us have, Joe Biden was elected in a time of almost unprecedented political chaos. The former presidency's time in office was defined by daily lies.

And the former president's loyal, lawless supporters violently and despicably attempted to throw out the results of an election in which there was simply no evidence of widespread voter fraud.

Biden won a year ago. Bigly. And the results are completely legitimate. But many on the losing side still insist the election was stolen. It wasn’t. 

Biden entered the White House at a time in which the American presidency itself had lost all standing worldwide. Biden has only begun to tend to the wounds the previous administration caused to our democracy.  

Have some of you really forgotten what Biden inherited? It was a bloody mess. We all had to endure a pandemic as well as a political scandal that dwarfed Watergate. 

Globally, the former president alienated virtually every American ally, and kissed up to and praised dictators.

While Biden is certainly not perfect, he is a good man and he is cleaning up the mess. He has re-engaged our allies. And slowly but steadily, Biden is bringing honor and decency back to the White House. 

And now, finally, his policies and plans are beginning to positively emerge. 

Historic China Lymphoma Project Is About to Take Flight

Lymphoma expert Dr. Jonathan Schatz (left), myself, and cancer researcher Dr. Zhizhong Li

It was just a little idea I had about a decade ago. But I am determined now to move move our China Lymphoma Project forward. Our first global conference, which took place several years ago at the Sanford Consortium for Regenerative Medicine in La Jolla, Calif. (above), was a terrific beginning. 

It was a lively, informative and inspirational event whose overriding theme was the friendship between scientists in China and scientists in the United States. The people of the two most powerful countries in the world have an enormous opportunity to move forward together through science. There were not many folks who thought we could pull this off. 

My original speech was widely embraced. And now I have returned to this project that I had to postpone.

 

I never listen to doubters. 

As we in the United States looked for ways to address the cancer crisis in China, where I have many friends and colleagues and where more than 7,500 people die of the disease each day, the consensus among many who attended the conference was that our little project was a positive thing that has the potential to make a real difference.  

While putting this project together, we worked side-by-side with such prestigious young biopharmaceutical companies in China as JW Therapeutics, InnoCare Pharma, and AntiCancer Bioscience.

Each of these companies has a game-changing lymphoma treatment approved for use and/or in clinical trials. And each of these companies has a presence in both China and the United States.  

 

And that is the key point here. These companies are involved in bringing new, state-of-the-art cancer treatments to both China and the United States.  And there are multiple United States companies that have a presence now in China.

 

Cancer knows of no boundaries. And lymphoma, especially, is a worldwide menace. As many of you know, I've been fighting lymphoma and writing about it for 25 years. My cancer recurred a few months ago after a 20-year plus remission, and I just recently saved my by choosing to go through CAR T immunotherapy. 

 

In China, lymphoma has been on the rise for the last decade. And it is already the fifth most common cancer in the US. 

Lymphoma is of course one of several types of cancer that is alarmingly on the rise in China, especially in urban areas where there are hazardous levels of pollution. 

But unlike lung cancer and some other cancers, lymphoma remained a great mystery to many people in China -- despite the fact that it was becoming much more common.

That has changed, as I predicted it would. China is now enjoying a biotech boom, especially with regard to blood cancer awareness and treatments and clinical trials, largely thanks to the companies I named above.

The government in China, too, is making a concerted effort to address the problem by, among other things, "declaring war" on air and water pollution, and of course by supporting the biotech industry's growth. 

 

There are a number of biotech companies in China that are now researching and marketing new lymphoma treatments, and the greatest thing about this boom is that it has generated several new partnerships between China and the US.

This remains a great and mostly untold story. US and China pharmaceutical companies are now partnering on projects and research. And this can only lead to positive things for the planet. 

The conference I held several years ago powerfully represented our project's mission, which was and is to bring our countries closer together under the banner of science. Our goal has not changed.

The idea is to leverage the latest communication technologies (social media, podcasts, smartphone apps and more) to provide much-needed information and hope, as well as comfort and compassion, to China's lymphoma cancer sufferers and their families and increase good will between our two great countries. 

When I started this, many people in China who received a lymphoma diagnosis just went home and gave up. The awareness of this type of cancer was just not widespread. Many believed it was a death sentence.

With access to new information about treatments and stories of Chinese people as well as others around the world who have been treated and are now doing fine, that has all changed. They now know that all types of lymphoma are treatable and beatable. 

A Global Gathering in La Jolla

Dr. Jonathan Schatz, a globally respected lymphoma physician and researcher from Sylvester Comprehensive Cancer Center at the University of Miami, pledged his and the hospital's support for the project, talked at our first conference about the need for more international cooperation between physicians, and suggested the project should pursue more epidemiological studies on lymphoma in China.

We are now moving moving closer to publishing our exclusive new e-book for China's lymphoma patients that profiles survivor stories, including famous China lymphoma survivors such as Kai-Fu Lee, the hugely popular micro-blogger and creator of Google China, as well as just regular folks (men, women and children) throughout China. 

This ebook will of course be FREE to China's lymphoma patients, and will be of course available in both Simplified Chinese and English.

Project Reaches Tipping Point

Our project now resonates with an increasingly broad audience worldwide. With all the social media, etc., it makes more sense than ever. We now expect this positive initiative to fly after a few starts and stops. 

 

As I told the gathering at my conference introduction back in 2016, the biotech and cancer hospital communities in both China and the US are eager to join us. Because everybody wins. 

The booming San Diego tech community is coming to us now, too, as are a variety of healthcare companies, doctors and more. And pretty much any science-focused company doing business in China or would like to and anyone who cares about China's people and about goodwill between the two most powerful countries in the world. We have positive and substantive relationships with several American universities, biotech leaders from China and the US, and more.

Support From Chinese Government Officials

Hua Liu, Consul of Science & Technology, Photos by Caitlin Prenga

Perhaps most importantly, there were also three representatives at that original conference from the Chinese Consulate General in Los Angeles, including our distinguished opening speaker Hua Liu (left), who at the time was Consul in Science and Technology. Members of the Consulate General's office warmly pledged their support. We look forward to working closely with them.

Other speakers at the conference included Dr. Huan-You Wang, a highly respected pathologist and lymphoma diagnostic expert at UCSD Moores Cancer Center, my personal cancer hospital. 

 

Dr. Wang stressed the need for all cancer patients to get the correct diagnosis, and noted that while there are many brilliant doctors and scientists in China, diagnosing cancer in China still has a long way to go. 

Typically, he said, pathologists in China were not specialists, they covered all diagnoses, not specific types of cancer. This, too, is changing as more hospitals learn about blood cancers and have access to new treatments and clinical trials. 

Dr. Catriona Jamieson, the acclaimed physician and expert in lymphoma and other blood cancers and Director of Stem Cell Research at the UCSD Moores Cancer Center, spoke brilliantly yet conversationally at our initial launch about the groundbreaking efforts at Moores to identify new ways to treat cancer, including lymphoma. 

She also explained a few of the encouragingly growing number of partnerships between cancer scientists in China and the US. This has increased many-fold since her speech, as she predicted it would.

Yours truly (left) and Dr. Jinghong Li

The final speaker was Dr. Jinghong Li (left),  an esteemed physician who trained at Peking University Health Science Center, Beijing. Jinghong gave a charming and informed talk about her work with cancer patients and others and expressed her deep gratitude and support for the project.

Please Support This Global Friendship Initiative

Let's get back on the horse. The China Lymphoma Project is seeking funding to fulfill our global mission of friendship through advanced science. Please support this historic project with a tax-deductible educational grant.

E-mail us at: sdsufan2000@gmail.com 

My cell is 858-397-4950

 

Xie-xie,

 

Jamie Reno
Founder and Director
The China Lymphoma Project

Oingo Boingo Lives!

Many Original Members of Quirky, Angry, Funny, Edgy, Underrated 80's Band Return!

 If you attended college in Southern California in the early-to-mid 1980's, you must remember Oingo Boingo, the quirky, hard-rocking band whose concerts were dance-and-sweat events. 

As a child of the 1970's, well, I had never seen or heard anything quite like them. I wasn't sure what to make of the band at first. But they grew on me.

When I was working part time as a coach and camp counselor at the Montecito YMCA in college, about half the kids on my sports teams were listening to Oingo Boingo on their Sony Walkmans.

 

One afternoon, I just had to borrow a kid's headset and listen in to see what all the fuss was about. It was immediately engaging, and also a bit disturbing and dangerous. I started dancing, and the kids on my team started laughing. 

 

They were happy to initiate their coach into the Boingo Universe. When you listen to Oingo Boingo, I realized that day, it's impossible to stay still.

 

The more I listened, the more I liked the creativity, the edginess, the reckless abandon, the just-plain fun. They were so different than anything else we heard on the radio in the early 80's.

 

They were punk-ish, but not punk. They were new wave-ish, but not new wave. They were alternative-ish, but not alternative. They were art rock-ish, but not art rock. They were ska-ish, but not ska . 

 

The band, which has been under-appreciated since the first record, created its own genre. Some call them Halloween Rock, 'cuz they had more than a small amount of anxious, scary/creepy themes and vibes, with references to nightmares and monsters and juvenile delinquents and insects underground.

Oingo Boingo did enjoy its 15 or perhaps 20 minutes of fame. I first saw them live at the US Festival in 1983 with my fellow 300,000 music fans. The band that day stole the show. 

 

They were funny, frenetic, obstinate, wacky, angry and musically gifted. They were jesters from Hell. I loved every minute of it. Of course, many of my fellow classic rock buddies thought they were lame and still do to this day. To each his own. 

I love those 70's arena rock bands. But I embraced the music of the 80's, too, and still do. I loved my MTV.

 

Oingo Boingo became hugely and deservedly popular in Southern California, if not quite as much so nationwide. The band had a great reputation as a superb live act. 

 

The band's biggest national moments came when they appeared in the Rodney Dangerfield comedy “Back to School” singing their hit "Dead Man's Party,' and when they recorded the title track of the movie comedy "Weird Science," and when they got their song "Goodbye" placed at the end of "Fast Times at Ridgemont High." 

Well, the good news is that most the original members of Oingo Boingo are back in a band called "Oingo Boingo Former Members." The band has a phenomenally talented new lead singer, but of course co-founder and undeniable genius Danny Elfman is still nowhere to be found.

Danny became a celebrated film composer, as many of you know, and never looked back. He's consistently, stubbornly refused to give the other original members of his former band the name, and he doesn't have any plans to resurrect the band. It kind of sucks. 

 

The good news is that seeing this band is a total Oingo Boingo experience. The new lead singer, Brendon McCreary, who is decades younger than his bandmates, is billed as an Oingo Boingo "superfan." He is a phenomenal talent. 

 

Arguably a better all-around and more versatile vocalist than even Danny, Brandon's command of the subtleties of the Oingo Bongo canon is remarkable.

 

So....  tonight we're gonna party like it's 1983! It's not too late for you to join us and re-live those college parties that you don't fully remember but you know we were there. The show doesn't start until 7:3o p.m. at Humphrey's By the Bay on Shelter Island.  There are still a few tickets available at Ticketmaster.

See you there!

PS -- Here's a partial list of songs by Oingo Boingo, if we missed some, let us know:

 

Acapella Ditty

Ain't This The Life

Bachelor Party

Ballad Of The Caveman

Better Luck Next Time

Burn Me Up

California Girls

Can't See (useless)

Change

Cinderella Undercover

Clowns Of Death

Controller

Cool City

Cry Of Vatos

Dead Man's Party

Dead Or Alive

Dream Somehow

Everybody Needs

Flesh 'n' Blood

Go Away

Goodbye 

Good For Your Soul

Grey Matter

Heard Somebody Cry

Helpless

Hey!

I Am The Walrus

I'm So Bad

Insanity

Insects

Is This

Just Another Day

Little Girls

Lost Like This

Mary

Nasty Habits

No One Lives Forever

No Spill Blood

Nothing Bad Ever Happens (To Me)

Nothing To Fear (but Fear Itself)

On The Outside

Only A Lad

Piggies

Reptiles And Samurai

Run Away (the Escape Song)

Stay

Take Your Medicine

The Cat Is Dead

Tough As Nails

Water

We Close Our Eyes

When The Lights Go Out

Where Do All My Friends Go

Who Do You Want To Be?

Whole Day Off

Why'd We Come (all This Way)

Wild Sex (in The Working Class)

You Got Your Baby Back